Cure Rare Disease (CRD) announced it has been awarded a $5.69 million grant from the California Institute for Regenerative ...

For the first time since 2019, Illinois regulators have approved new medical conditions to qualify for medical cannabis, all centered around women’s health. Endometriosis, ovarian cysts, uterine ...

idiopathic pulmonary fibrosis and spinocerebellar ataxia 2. BioNTech, springboarding off its global COVID-19 mRNA vaccine successes, touted pushes into mRNA-based cancer immunotherapies and anti-PD-1 ...

The current human tissue-based study provides convincing evidence correlating hippocampal expressions of RNA guanine-rich G-quadruplexes with aging and with Alzheimer's Disease presence and severity.

In a preclinical rodent model of CHIP-related ataxia, we observed that CHIP mutations lead to increased levels of phosphodiesterase 9A (PDE9A), whose role in this context remains poorly understood.

Troriluzole: Troriluzole is a novel glutamate modulator currently in Phase 3 development for Spinocerebellar ataxia and obsessive-compulsive disorder. A new drug application was submitted to US ...

SPRINGFIELD, Ill. – The Illinois Department of Public Health (IDPH) has approved four new conditions for treatment with medicinal cannabis, a first in six years. Approved under Illinois law ...

In addition, manual searches were performed with relevant keywords such as “cerebellum,” “spinocerebellar degeneration,” “ataxia,” “physiotherapy,” and “rehabilitation.” The studies identified in the ...

Of the 15 neurological disorders listed, some of which have symptoms of progeria, six—spinocerebellar ataxia with axonal neuropathy-1, Huntington's disease, Alzheimer's disease, Parkinson's ...

As ataxias espinocerebelares (SCA) são um grupo clínico e geneticamente heterogêneo de doenças monogênicas que compartilham ataxia e herança autossômica dominante como características principais. Uma ...

Two years into her spinocerebellar ataxia diagnosis, Bachelor star Megan Marx shared that 2024 was “one of the best years of my life”— and she’s got a robust list of goals for 2025.

Acetylleucine (IB-1001) is under development for the treatment of Niemann-Pick disease type C, GM1 Gangliosidosis, GM2 gangliosidosis, ataxia telangiectasia, spinocerebellar ataxia, Tay-Sachs Disease, ...